What is US Patent 3480626 for Trospium Chloride?
US Patent 3480626 describes a method for synthesizing trospium chloride [1]. The patent, filed in 1967 and granted in 1969, details a process involving the esterification of benzilic acid with 3-hydroxytropane in the presence of a dehydrating agent [1]. This reaction yields trospium, which is then converted to its chloride salt [1].
How is Trospium Chloride Synthesized According to the Patent?
The patented synthesis of trospium chloride involves reacting benzilic acid with 3-hydroxytropane. This esterification is facilitated by a dehydrating agent, such as phosphorus oxychloride or thionyl chloride, which removes water formed during the reaction [1]. The product of this reaction is trospium, which is then isolated and treated with hydrochloric acid to form the stable trospium chloride salt [1]. The patent outlines purification steps, including recrystallization, to obtain the final product [1].
What is Trospium Chloride Used For?
Trospium chloride is a muscarinic antagonist used to treat urinary incontinence, particularly urge incontinence [2]. It works by blocking the action of acetylcholine on bladder muscles, reducing involuntary contractions and increasing bladder capacity [2].
When Does US Patent 3480626 Expire?
As a patent granted in 1969, US Patent 3480626 would have expired long ago. U.S. patents generally have a term of 17 years from the date of grant for applications filed before June 8, 1995. Therefore, this patent expired by the early 1980s [3].
Are There Other Patents Related to Trospium Chloride Synthesis?
While US Patent 3480626 covers an early synthesis method, later patents likely exist for improved synthesis processes, polymorphic forms, or novel formulations of trospium chloride [4]. These subsequent patents would have been filed and granted much more recently, offering different intellectual property protections.
What are the Side Effects of Trospium Chloride?
Common side effects associated with trospium chloride include dry mouth, constipation, blurred vision, and urinary retention [2]. Less common side effects can include dizziness, drowsiness, and rapid heartbeat [2].
How Does Trospium Chloride Compare to Other Overactive Bladder Medications?
Trospium chloride is an anticholinergic medication, similar to oxybutynin, tolterodine, and solifenacin. While all aim to reduce bladder overactivity, they may differ in their side effect profiles, efficacy, and routes of administration [5]. Some newer medications may offer improved tolerability or different mechanisms of action [5].
Sources
1. US Patent 3480626A. https://patents.google.com/patent/US3480626A/en
2. National Institute of Diabetes and Digestive and Kidney Diseases. (n.d.). Urinary Incontinence in Women. https://www.niddk.nih.gov/health-information/urologic-diseases/urinary-incontinence-women
3. United States Patent and Trademark Office. (n.d.). Patent Basics. https://www.uspto.gov/patents/basics
4. Google Patents. (n.d.). Search for Trospium Chloride Patents. https://patents.google.com/?q=trospium+chloride
5. National Health Service. (2022, October 17). Overactive bladder (OAB). https://www.nhs.uk/conditions/overactive-bladder/